Clinical trials for B-cell chronic lymphocytic leukemia
100 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center · PI: Mazyar Shadman, MD, MPH
- RECRUITINGEarly Phase 1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI) · PI: Laura S Samples, M.D.
- RECRUITINGPhase 4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
- RECRUITINGPhase 1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center · PI: Geoffrey Shouse
- RECRUITINGPhase 2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPhase 2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer · PI: Zulfa Omer
- RECRUITINGPhase 2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn · PI: Inhye Ahn, MD
- RECRUITINGPhase 2NCT07221500A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)Nurix Therapeutics, Inc. · PI: Nurix Study Director
- RECRUITINGNCT07099443Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic LeukemiaNantes University Hospital · PI: Anne LOK, MD, PhD
- ENROLLING BY INVITATIONNCT07173790Watch and Wait or Worry and Wait in Indolent LymphomaSeoul National University Hospital · PI: Ja Min Byun, MD, PhD
- RECRUITINGPhase 2NCT06520098A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)VA Office of Research and Development · PI: Suman Kambhampati, MD MBBS
- RECRUITINGPhase 2NCT07154264A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)Dizal (Jiangsu) Pharmaceutical Co., Ltd. · PI: Niu
- RECRUITINGPhase 3NCT07139873A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)Dizal (Jiangsu) Pharmaceutical Co., Ltd. · PI: Study Director
- RECRUITINGPhase 2NCT07108998Study of Epcoritamab as a Consolidation Therapy in CLL/SLLZulfa Omer
- RECRUITINGPhase 1NCT06735664Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's TransformationCity of Hope Medical Center · PI: Alexey V Danilov
- RECRUITINGPhase 2NCT06967610Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).M.D. Anderson Cancer Center · PI: Alessandra Ferrajoli, MD
- RECRUITINGPhase 3NCT06943872A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)BeOne Medicines · PI: Study Director
- RECRUITINGPhase 2NCT06839053Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell LymphomaFred Hutchinson Cancer Center · PI: Mazyar Shadman, MD, MPH
- RECRUITINGPhase 3NCT06970743A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsBeOne Medicines · PI: Study Director Study Director
- RECRUITINGPhase 4NCT06876662A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin LymphomaEli Lilly and Company · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
- RECRUITINGPhase 2NCT06849713Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLLMassachusetts General Hospital · PI: Jacob Soumerai, MD
- RECRUITINGPhase 3NCT06846671A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsBeOne Medicines · PI: Study Director
- RECRUITINGPHASE1, PHASE2NCT06644183Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)Jennifer R. Brown, MD, PhD · PI: Jennifer Brown, MD, PhD
- RECRUITINGNCT06784167Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T TreatmentOHSU Knight Cancer Institute · PI: Amrita Desai
- RECRUITINGEarly Phase 1NCT0663617564Cu-LLP2A for Imaging Hematologic MalignanciesWashington University School of Medicine · PI: Farrokh Dehdashti, M.D.
- RECRUITINGNCT06788639A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company · PI: Bristol-Myers Squibb
- RECRUITINGPhase 4NCT06651970Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureAstraZeneca
- RECRUITINGNCT06821880Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID ProjectMedical University Innsbruck
- RECRUITINGPHASE1, PHASE2NCT06564038A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesAstraZeneca
- ACTIVE NOT RECRUITINGPhase 1NCT06291220A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)AbbVie · PI: ABBVIE INC.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06697184A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.BeiGene · PI: Study Director
- RECRUITINGPhase 1NCT06208735CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesBritish Columbia Cancer Agency · PI: Kevin Hay, MD
- ENROLLING BY INVITATIONPhase 1NCT06788509A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringJanssen Research & Development, LLC · PI: Janssen Research and Development, LLC Clinical Trial
- RECRUITINGPhase 2NCT06466122Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKiKerry Rogers · PI: Kerry A Rogers, MD
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06762431Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.Vitebsk Regional Clinical Cancer Centre
- ACTIVE NOT RECRUITINGPhase 2NCT06253637Daratumumab in VHR T-ALL Treated According to the ALL National Treatment ProgramGruppo Italiano Malattie EMatologiche dell'Adulto · PI: Sabina Chiaretti
- RECRUITINGPHASE1, PHASE2NCT06364423Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for LeukemiasNational Cancer Institute (NCI) · PI: James N Kochenderfer, M.D.
- RECRUITINGPhase 2NCT06544785Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPETHEMA Foundation · PI: Pau Abrisqueta
- ACTIVE NOT RECRUITINGPhase 2NCT06524375A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment PeriodGenentech, Inc. · PI: Clinical Trials
- RECRUITINGNCT06508684Current Status of BTKi Treatment for CLL/SLL in ChinaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPhase 2NCT05963074A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic LeukemiaJanssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- RECRUITINGPHASE2, PHASE3NCT06378138ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)Beijing InnoCare Pharma Tech Co., Ltd.
- RECRUITINGPhase 2NCT06333262Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic LeukemiaInhye Ahn · PI: Inhye E Ahn, MD
- RECRUITINGN/ANCT05950997A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLLThe First Affiliated Hospital with Nanjing Medical University · PI: Jianyong Li, PhD, MD
- RECRUITINGPHASE1, PHASE2NCT05791409Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLLStichting Hemato-Oncologie voor Volwassenen Nederland
- RECRUITINGPhase 3NCT06319456A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.Ascentage Pharma Group Inc. · PI: Lugui Qiu, M.D., Ph.D.
- RECRUITINGPhase 1NCT06191887B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesMayo Clinic · PI: Mohamed A. Kharfan-Dabaja, M.D., M.B.A.
- RECRUITINGN/ANCT06102330Multicenter HomeVENT: Home Values and Experiences Navigation TrackJohns Hopkins University · PI: Renee Boss, MD
- RECRUITINGPhase 2NCT06043674Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationChristine Ryan · PI: Christine Ryan, MD
- RECRUITINGNCT06151730Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT StudyMayo Clinic · PI: Joerg Herrmann, MD
- RECRUITINGPhase 2NCT05672251Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center · PI: Swetha Kambhampati
- ACTIVE NOT RECRUITINGPhase 1NCT06547944Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGN/ANCT07487428CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLLTechnical University of Munich · PI: Maike Buchner-Mayr, PD Dr.
- RECRUITINGPhase 3NCT06104566Global Trial in APG2575 for Patients With CLL/SLLAscentage Pharma Group Inc.
- ACTIVE NOT RECRUITINGPhase 1NCT05971251Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaUniversity of Alabama at Birmingham · PI: Aditi Saha, M.D.
- RECRUITINGPhase 3NCT06136559A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Merck Sharp & Dohme LLC · PI: Medical Director
- ACTIVE NOT RECRUITINGNCT06170671REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in RomaniaAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT05869279Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic LeukemiaFondazione Matilde Tettamanti Menotti De Marchi Onlus · PI: Andrea Biondi, MD
- RECRUITINGPhase 2NCT05694312Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGNCT06125795A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in SpainAbbVie · PI: ABBVIE INC.
- RECRUITINGPHASE1, PHASE2NCT05959694A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPhase 1NCT05943496Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaOHSU Knight Cancer Institute · PI: Stephen E Spurgeon
- RECRUITINGPhase 1NCT06547528A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLLOno Pharmaceutical Co. Ltd · PI: Project Leader
- ACTIVE NOT RECRUITINGPhase 1NCT05797233Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell MalignanciesNational Cancer Institute (NCI) · PI: James N Kochenderfer, M.D.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05944978A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological MalignanciesSichuan Baili Pharmaceutical Co., Ltd. · PI: Lugui Qiu, MS
- RECRUITINGPhase 3NCT05947851A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGPhase 2NCT05672355A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic LeukemiaCity of Hope Medical Center · PI: Alexey V Danilov
- RECRUITINGPhase 1NCT05602363AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin LymphomaCarna Biosciences, Inc.
- RECRUITINGPhase 2NCT05873712Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's SyndromeAseel Alsouqi · PI: Jennifer A Woyach, MD
- RECRUITINGNCT06203652The Pathogenesis and Prognostic Factors of LymphomaShanghai Zhongshan Hospital
- RECRUITINGPhase 2NCT04941716Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialFred Hutchinson Cancer Center · PI: Mazyar Shadman
- ACTIVE NOT RECRUITINGPhase 2NCT05718869Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL StudyCity of Hope Medical Center · PI: Matthew Mei
- RECRUITINGPhase 1NCT05512390A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)AbbVie · PI: ABBVIE INC.
- ACTIVE NOT RECRUITINGPhase 1NCT05665062Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic MalignanciesSynthekine
- ACTIVE NOT RECRUITINGPhase 3NCT05624554A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)Merck Sharp & Dohme LLC · PI: Medical Director
- ACTIVE NOT RECRUITINGPhase 2NCT05677919Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic LeukemiaMayo Clinic · PI: Yucai Wang, MD, PhD
- RECRUITINGPhase 2NCT05388006Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaMayo Clinic · PI: Paul J. Hampel, MD
- RECRUITINGPhase 2NCT05536349Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)M.D. Anderson Cancer Center · PI: Nitin Jain, MD
- ACTIVE NOT RECRUITINGPhase 3NCT05556720Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical TrialMonash University · PI: James H McMahon, MBBS PhD
- ACTIVE NOT RECRUITINGPhase 2NCT05479994Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaBeiGene
- RECRUITINGPhase 4NCT05170399Vaccine Responses in Patients With B Cell MalignanciesNational Heart, Lung, and Blood Institute (NHLBI) · PI: Adrian U Wiestner, M.D.
- RECRUITINGPhase 2NCT05336812Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic LeukemiaOhio State University Comprehensive Cancer Center · PI: Kerry S Rogers, MD
- ACTIVE NOT RECRUITINGNCT05437250National Acalabrutinib Observational StudyAstraZeneca · PI: Anne Quinquennel, Doctor
- ACTIVE NOT RECRUITINGPhase 3NCT05057494A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaAstraZeneca
- RECRUITINGPhase 3NCT05254743A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Loxo Oncology, Inc. · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
- ACTIVE NOT RECRUITINGPhase 2NCT05458297A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGNCT04785989In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)University of Wisconsin, Madison · PI: Christopher Fletcher, MD
- RECRUITINGN/ANCT06475469Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious RiskCHU de Reims
- RECRUITINGPHASE1, PHASE2NCT05294731Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderBeiGene · PI: Study Director
- RECRUITINGPhase 3NCT05197192A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLGerman CLL Study Group · PI: Barbara Eichhorst, MD, Prof.
- RECRUITINGPhase 2NCT04895436Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)AbbVie · PI: ABBVIE INC.
- RECRUITINGNCT06250465AGMT Austrian CLL (Chronic Lymphocytic Leukemia) RegistryArbeitsgemeinschaft medikamentoese Tumortherapie · PI: Richard Greil, MD
- RECRUITINGPhase 2NCT05168930Zanubrutinib and Venetoclax in CLL (ZANU-VEN)Dana-Farber Cancer Institute · PI: Inhye E Ahn, MD
- RECRUITINGPhase 2NCT05183854Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL TrialUniversity of Utah · PI: Daniel Ermann, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05069051Belimumab in Patients with Chronic Lymphocytic LeukemiaUniversity Hospital Tuebingen · PI: Juliane Walz, Prof.Dr.
- RECRUITINGPhase 2NCT05147467Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLAscentage Pharma Group Inc. · PI: Yifan Zhai, M.D., Ph.D.
- ACTIVE NOT RECRUITINGNCT05140369CLL Therapy Approaches in RussiaAstraZeneca
- ACTIVE NOT RECRUITINGPhase 2NCT04963946STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic LeukemiaFrench Innovative Leukemia Organisation · PI: Loïc Ysebaert, Pr
- ACTIVE NOT RECRUITINGPhase 3NCT05023980A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Loxo Oncology, Inc. · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)